Recombinant human interleukin 6 in metastatic renal cell cancer: A phase II trial

British Journal of Cancer

Volumn 73, Issue 6, 1996, Pages 789-793

  Stouthard, J M L ^a   Goey, H ^b   De Vries, E G E ^c   De Mulder, P H ^d   Groenewegen, A ^e   Pronk, L ^b   Stoter, G ^b   Sauerwein, H P ^a   Bakker, P J M ^a   Veenhof, C H N ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Sandoz Medical Research Department   (Netherlands)

Author keywords

Human; Interleukin 6; Interleukins; Renal cell cancer

Indexed keywords

ACUTE PHASE PROTEIN; ANTIBODY; BISPHOSPHONIC ACID DERIVATIVE; PARACETAMOL; RECOMBINANT INTERLEUKIN 6;

ADULT; AGED; ANEMIA; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG TOXICITY; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN CELL; HYPERCALCEMIA; KIDNEY CARCINOMA; LEUKOCYTOSIS; LIVER TOXICITY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN INDUCTION; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOSIS; VERTIGO; VOMITING; WEIGHT REDUCTION;

EID: 9244227559     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.137     Document Type: Article

References (29)

1. BLAY J-Y, NEGRIER S, COMBARET V, ATTALI S, GOILLOT E, MERROUCHE Y, MERCATELLO A, RAVOULT A AND TOURANI JM. (1992). Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res., 52, 3317-3322.
2. 2. Proc. Natl Acad. Sci. USA, 85, 8037-8041.
3. GAULDIE J, RICHARDS C AND BAUMANN H. (1992). IL-6 and the acute phase reaction. Res. Immunol., 143, 755-759.
4. GOGUSEV J, AUGUSTI M, CHRÉTIEN Y AND DROZ D. (1993). Interleukin-6 and TNFα production in human renal cell carcinoma. Kidney Int., 44, 585-592.
5. GRUSS HJ, BRACH MA, MERTELSMANN RH AND HERRMANN F. (1991). Interferon-gamma interrupts autocrine growth mediated by endogenous interleukin-6 in renal cell carcinoma. Int. J. Cancer, 49, 770-773.
6. HOUSSIAU F AND VAN SNICK J. (1992). IL-6 and the T-cell response. Res. Immunol., 143, 740-743.
7. ISHIBASHI T AND ASANO S. (1992). IL-6 and thrombocytopoiesis. Res. Immunol., 143, 752-754.
8. KISHIMOTO T AND HIRANO T. (1988). Molecular regulation of B lymphocyte response. Ann. Rev. Immunol., 6, 485-512.
9. KOO AS, AMSTRONG C, BOCHNER B, SHIMABUKURO T, TSO CL, DEKERNION JB AND BELLDEGRUN A. (1992). Interleukin-6 and renal cell cancer: production, regulation and growth effects. Cancer Immunol. Immunother., 35, 97-105.
10. LE J AND VILCEK J. (1989). Biology of disease. Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab. Invest., 61, 588-602.
11. MARSTON LINEHAM W, SHIPLEY WU AND LONGO DL. (1989). Cancer of the kidney and ureter. In Cancer: Principles and Practice of Oncology, (3rd ed.), DeVita Jr VT, Hellman S and Rosenberg SA (eds.) pp. 979-1007. J.B. Lippincott: Philadelphia.
12. MIKI S, IWANO M, MIKI Y, YAMAMOTO M, TANG B, YOKOKAWA K, SONODA T, HIRANO T AND KISHIMOTO T. (1989). Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett., 250, 607-610.
13. MULÉ JJ, MCINTOSH JK, JABLONS DM AND ROSENBERG SA. (1990). Antitumour activity of recombinant interleukin-6 in mice. J. Exp. Med., 171, 629-636.
14. MULÉ JJ, CUSTER MC, TRAVIS WD AND ROSENBERG SA. (1992). Cellular mechanisms of antitumour activity of recombinant IL-6 in mice. J. Immunol., 148, 2622-2629.
15. PORGADOR A, TZEHOVAL E, KATZ A, VADAI E, REVEL M, FELDMAN M AND EIDENBACH L. (1992). Interleukin-6 gene transfection into Lewis lung carcinoma tumour cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res., 52, 3679-3686.
16. RAVOET C, DEGRÈVE J AND VANDEWOUDE K. (1994). Tumour stimulating effects of recombinant human interleukin-6. Lancet, 344, 1576-1577.
17. REVEL M. (1992). Growth regulatory functions of IL-6 and antitumour effects. Res. Immunol., 143, 769-773.
18. SIMON R. (1987). How large should a phase II trial of a new drug be? Cancer Treat. Rep., 71, 1079-1085.
19. STADLER WM, RICHARDS JM AND VOGELZANG NJ. (1992). Serum interleukin-6 levels in metastatic renal cell carcinoma: correlation with survival but not an independent prognostic indicator. J. Natl Cancer Inst., 84, 1835-1836.
20. STOUTHARD JML, VAN DER POLL T, ENDERT E, BAKKER PJM, VEENHOF CHN, SAUERWEIN HP AND ROMIJN JA. (1994). Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans. J. Clin. Endocrinol. Metab., 79, 1342-1346.
21. STOUTHARD JML, ROMIJN JA, VAN DER POLL T, ENDERT E, KLEIN S, BAKKER PJM, VEENHOF CHN AND SAUERWEIN HP. (1995). The endocrinologic and metabolic effects of interleukin-6 in humans. Am. J. Physiol., 268, E813-E819.
22. TAKAHASHI N, BROUCKAERT P AND FIERS W. (1991). Induction of tolerance allows separation of lethal and anti-tumor activities of tumor necrosis factor in mice. Cancer Res., 51, 2366-2372.
23. TSUKAMOTO T, KUMAMOTO Y, MIYAO N, MASUMORI N, TAKAHASHI A AND YANASE M. (1992). Interleukin-6 in renal cell carcinoma. J. Urol., 148, 1778-1782.
24. VAN GAMEREN M, WILLEMSE PHB, MULDER NH, LIMBURG PC, GROEN HS, VELLENGA E AND DE VRIES EGE. (1994). Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood, 84, 1434-1441.
25. VANTONGELEN K. (ed.) (1991). National Cancer Institute of Canada Clinical Trials Group Expanded Common Toxicity Criteria. A Practical Guide to EORTC Studies, pp 119-131.
26. WEBER JS, YANG JC, TOPALIAN SL, PARKINSON DR, SCHWART-ZENRTUBER DS, ETTINGHAUSEN SE, GUNN H, MIXON A, KIM H, COLE D, LEVIN R AND ROSENBERG SA. (1993). Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol., 11, 499-506.
27. WEISS GR, MARGOLIN KA, SZNOL M, ATKINS MB, OLEKSOWICZ L, ISAACS R AND FISHER RI. (1994). A phase II trial of a 120-hour continuous intravenous (CIV) infusion of interleukin-6 (rHuIL-6) for metastatic renal cell carcinoma (RCC). (abstract). Proc. ASCO, 13, 248.
28. WIRTH MP. (1993). Immunotherapy for metastatic renal cell carcinoma. Urol. Clin. N. Am., 20, 283-295.
29. YAGODA A, PETRYLAK D AND THOMPSON. (1993). Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol. Clin. N. Am., 20, 303-321.